Respondent summary statistics (N = 384)
| Name . | Statistic . |
|---|---|
| Age, mean (SD), range, y | 64.6 (9.7) 30, 89 |
| Female | 53 |
| White | 94 |
| Black or African American | 4 |
| Private insurance* | 70 |
| Public insurance (Medicare, Medicaid, or Veterans Health Insurance) | 69 |
| Employed full-time | 24 |
| Employed part-time | 9 |
| Retired from employment | 48 |
| Time since first diagnosed with CLL, mean (SD), range, y | 9.4 (6.4) 1, 58 |
| Treatment naive | 20 |
| First-line treatment | 23 |
| Relapsed/refractory treatment | 39 |
| Other treatment† | 17 |
| Currently receiving treatment of CLL | 38 |
| Ever received oral therapy (pills) for CLL | 39 |
| Ever received IV therapy for CLL | 72 |
| Received financial aid (n = 301)‡ | 53 |
| Ability to pay out-of-pocket costs (n = 142)§ | |
| Very difficult | 13 |
| Difficult | 27 |
| Neither difficult nor easy | 42 |
| Easy | 11 |
| Very easy | 6 |
| Participated in a clinical trial | 26 |
| Lives in a rural area | 17 |
| Lives in a suburban area | 58 |
| Lives in an urban area | 23 |
| Previously had a bone marrow aspiration test | 67 |
| Name . | Statistic . |
|---|---|
| Age, mean (SD), range, y | 64.6 (9.7) 30, 89 |
| Female | 53 |
| White | 94 |
| Black or African American | 4 |
| Private insurance* | 70 |
| Public insurance (Medicare, Medicaid, or Veterans Health Insurance) | 69 |
| Employed full-time | 24 |
| Employed part-time | 9 |
| Retired from employment | 48 |
| Time since first diagnosed with CLL, mean (SD), range, y | 9.4 (6.4) 1, 58 |
| Treatment naive | 20 |
| First-line treatment | 23 |
| Relapsed/refractory treatment | 39 |
| Other treatment† | 17 |
| Currently receiving treatment of CLL | 38 |
| Ever received oral therapy (pills) for CLL | 39 |
| Ever received IV therapy for CLL | 72 |
| Received financial aid (n = 301)‡ | 53 |
| Ability to pay out-of-pocket costs (n = 142)§ | |
| Very difficult | 13 |
| Difficult | 27 |
| Neither difficult nor easy | 42 |
| Easy | 11 |
| Very easy | 6 |
| Participated in a clinical trial | 26 |
| Lives in a rural area | 17 |
| Lives in a suburban area | 58 |
| Lives in an urban area | 23 |
| Previously had a bone marrow aspiration test | 67 |
Data are reported as percentage of respondents unless otherwise indicated.
SD, standard deviation.
There is overlap between the private and public insurance categories, as many respondents have both private and public insurance.
Other includes respondents who provided answers that did not fit the categories for treatment naive, first line, or relapsed/refractory.
Those who stated they had received at least 1 treatment of CLL were asked, “Some patients find it difficult to pay for their CLL treatment. Do you currently or have you ever received financial assistance from a patient support program through your doctor, hospital, drug maker or from a patient organization such as the Leukemia and Lymphoma Society or the Lymphoma Research Foundation?”
Among respondents who have received at least 1 treatment and paid some amount for treatment, “How difficult did you find it to pay your out-of-pocket costs for your current or most recent CLL treatment?”